Dan Devine

Dan Devine has a strong and extensive work experience spanning several companies and roles. Dan currently holds the position of Chief Business Officer/General Counsel/EVP at Vaxxas since February 2022. Prior to this, they were a member of the Regenerative Medicine Research Fund Advisory Committee at Connecticut Innovations from January 2015 to March 2023. From September 2012 to March 2023, they served as the SVP of New Technologies at Mesoblast Limited. Earlier in their career, Dan was the CEO and Founder of Patrys Limited from May 2002 to June 2011, where they played a crucial role in leading the company through various stages, including an initial public offering on the ASX. Dan also served on the Board of Directors of Patrys Limited from May 2007 to May 2011. Dan worked as an Executive Consultant at Angioblast (Mesoblast Subsidiary) from May 2004 to March 2006. Dan gained valuable experience in international business development as the Head of International Bus Dev at Pfizer from 1999 to 2001. Prior to that, they held the position of Vice President at Warner Lambert from June 1995 to May 1999, where they played a key role in establishing international corporate, manufacturing, supply chain, and marketing structures. Dan began their career as a Senior Associate in Corporate Structuring at Dewey Ballantine from July 1989 to March 1995. Overall, Dan Devine has shown their expertise in various leadership and advisory roles, contributing significantly to the growth and success of the organizations they have been associated with.

Dan Devine has a diverse education history. Dan first attended Cornell University from 1982 to 1986, where they obtained a Bachelor's degree in Economics. Following that, they went on to the University at Buffalo School of Law from 1986 to 1989, earning a JD degree in Law. Later, from 1998 to 2000, they attended the Columbia Business School and completed an MBA degree with a concentration in Business.